136 related articles for article (PubMed ID: 38318778)
21. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
22. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
23. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
24. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
25. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
[TBL] [Abstract][Full Text] [Related]
26. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.
Mattioli R; Ilari A; Colotti B; Mosca L; Fazi F; Colotti G
Mol Aspects Med; 2023 Oct; 93():101205. PubMed ID: 37515939
[TBL] [Abstract][Full Text] [Related]
28. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
29. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
30. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
31. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner.
Durham KK; Chathely KM; Mak KC; Momen A; Thomas CT; Zhao YY; MacDonald ME; Curtis JM; Husain M; Trigatti BL
Am J Physiol Heart Circ Physiol; 2018 Jan; 314(1):H31-H44. PubMed ID: 28986362
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.
Lothstein L; Rodrigues PJ; Sweatman TW; Israel M
Anticancer Drugs; 1998 Jan; 9(1):58-66. PubMed ID: 9491793
[TBL] [Abstract][Full Text] [Related]
33. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
[TBL] [Abstract][Full Text] [Related]
34. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
35. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
38. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.
Barrett CM; Lewis FL; Roaten JB; Sweatman TW; Israel M; Cleveland JL; Lothstein L
Mol Cancer Ther; 2002 May; 1(7):469-81. PubMed ID: 12479265
[TBL] [Abstract][Full Text] [Related]
39. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients.
Kakadekar AP; Sandor GG; Fryer C; Chan KW; Rogers PC; Pritchard S; Popov R
Med Pediatr Oncol; 1997 Jan; 28(1):22-6. PubMed ID: 8950332
[TBL] [Abstract][Full Text] [Related]
40. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.
Scotlandi K; Perdichizzi S; Bernard G; Nicoletti G; Nanni P; Lollini PL; Curti A; Manara MC; Benini S; Bernard A; Picci P
Eur J Cancer; 2006 Jan; 42(1):91-6. PubMed ID: 16326096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
